drugset / Trial / NCT00912860

Immunogenicity and Safety Study of Serum-Free Avonex

NCT00912860

Phase 2 Completed 155 enrolled Biogen
NaSingle-groupOpen-labelBasic science

Summary

To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.

Timeline

Start
2003-01
Primary completion
2004-12
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1a Protein / enzyme biologic Intramuscular

Indications